Professor Mark Humphries is a Chair in Computational Neuroscience at the University of Nottingham, and author of “The Spike: An Epic Journey Through the Brain in 2.1 Second”. His lab’s work focuses on how neurons collectively encode information, and how that goes wrong in movement disorders.
Prof. Mark Humphires delved into our brain, drawing on decades of research in neuroscience, exploring how billions of neurons communicate with each other. His topic is “Why the brain uses spikes and what that means for brain disorders?”
The passing of spikes between neurons is what creates our thoughts, words, and deeds. Errors in our thoughts, words, and deeds in brain disorders must ultimately arise from errors in the sending of spikes. Understanding what spikes do and why the brain uses them will give us a common language for understanding brain disorders.
Yuriy leads the Data Science Team developing computer vision algorithms for neurological motor diseases and designing clinical and analytical validation studies for computer vision devices such as Machine Medicine’s flagship product, Kelvin, a video-based motor assessment platform for movement disorders.
During the meetup he will share his extensive practical experience while talking about “Safe and effective AI-powered medical devices: developer and regulatory points of view”. The successes of the AI applications see a larger adoption of automated solutions on healthcare. AI systems create unique challenges for developers and regulatory authorities that are not seen before in general software development. An overview of such challenges and the way Machine Medicine tackles them will be the central topic of the talk.
Yuriy is a co-author of insightful publications in the field of video-based assessments of motor diseases – “Video-based activity recognition for automated motor assessment of Parkinson’s disease” (2023), “Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population” (2023), “An Evaluation of KELVIN, an Artificial Intelligence Platform, as an Objective Assessment of the MDS UPDRS Part III” (2022) and “Clinically interpretable severity estimation of facial expression impairment in Parkinson’s disease” (2022).